2 deficiency is a clinically underrecognized genetic disorder that confers a predisposition for chronic obstructive pulmonary disease (COPD) and/or liver disease (1) (2) (3) (4) . In general, serum reference values for ␣ 1 AT concentration range from 1.0 g/L to 3.5 g/L, and a clinical threshold of 0.8 -1.0 g/L is often used for diagnostic purposes (4) (5) (6) . Genetic epidemiologic surveys suggest that ␣ 1 AT deficiency may affect 1 in about 1 500 individuals in Europe (7 ) . Worldwide, ␣ 1 AT deficiency has been estimated to affect 3.4 million individuals, in all racial subgroups (7 ) . ␣ 1 AT, an acute-phase protein of 394 amino acid residues (52 kDa), is produced in the liver and reaches the lungs by diffusion from the circulation; ␣ 1 AT is also produced locally in macrophages and bronchial epithelial cells (8 ) . The SERPINA1 3 [serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1] gene is located on the long arm of chromosome 14 (14q31-32.3). It spans 12.2 kb and is organized into 4 coding exons (2, 3, 4, and 5) and 3 noncoding exons (1a, 1b, and 1c). At least 100 different ␣ 1 AT alleles have been identified (5 ) . The alleles associated with disease can be classified according to their pathogenic mechanism. The deficient alleles lead to intracellular ␣ 1 AT accumulation (e.g., the Z allele, Glu 342 3 Lys) or degradation, such that less (e.g., the S allele, Glu 264 3 Val) or none (e.g., the M heerlen allele, Pro 369 3 Leu) of the protein is released into the circulation (4) (5) (6) (7) (8) (9) . The null alleles are characterized by an absence of circulating ␣ 1 AT protein because of transcriptional or translational errors that interrupt synthesis. The dysfunctional alleles have an abnormal ␣ 1 AT function, characterized by a decreased or absent elastase-inhibitory activity. Some deficient ␣ 1 AT variants, such as the Z and M malton alleles, not only produce a predisposition to lung emphysema but also cause the development of liver cirrhosis, owing to pathologic polymerization of these specific ␣ 1 AT variants within the endoplasmic reticulum of hepatocytes (3, (8) (9) (10) .
Although ␣ 1 AT deficiency is one of the most prevalent and potentially lethal hereditary disorders, it is underrecognized by clinicians and is seldom diagnosed before clinical symptoms, such as COPD, have developed. ␣ 1 AT concentrations in individuals with the 2 most frequently occurring deficiency genotypes (ZZ homozygotes and SZ compound heterozygotes) are thought to be insufficient to ensure lifetime protection of the lungs from proteolytic damage by elastase, especially in smokers (11 ) . Besides the SZ and ZZ allele combinations, a combination of other deficient, dysfunctional, or null alleles at the ␣ 1 AT locus may lead to a deficient ␣ 1 AT concentration (4) (5) (6) . The evidence suggests that only 0.41% and 0.35% of ZZ homozygotes and SZ compound heterozygotes, respectively have been recognized (12 ) . In addition, surveys have revealed that the mean (SD) intervals between the first symptoms and the initial diagnosis of ␣ 1 AT deficiency range from 5.6 (8.5) years to 8.3 (6.9) years (13, 14 ) . Because a delay in the diagnosis of ␣ 1 AT deficiency also delays opportunities for specific counseling and therapy, efforts to enhance clinicians' diagnostic recognition of the disorder are expanding worldwide. The guidelines of the American Thoracic Society and the European Respiratory Society therefore strongly recommend testing for ␣ 1 AT deficiency in all individuals with COPD, asthma, or emphysema and advise testing for family members of ␣ 1 AT-deficient patients (15 ) .
In many laboratories, a diagnostic workup currently implies quantification of ␣ 1 AT antigen and subsequent phenotyping of the ␣ 1 AT protein by isoelectric focusing (IEF) when concentrations are low or when a pedigree analysis is needed to clarify familial patterns. This approach inevitably leads to misdiagnoses; for instance, clinically relevant null alleles will be missed with IEF (16, 17 ) . Therefore, we replaced IEF with direct sequencing of the relevant parts of the ␣ 1 AT gene, enabling an efficient and reliable approach to a risk inventory of the index patient and the family. Our application of this approach has identified 2 new null alleles.
Patients and Methods

PATIENTS
In our hospital, requests for measurements of the ␣ 1 AT antigen concentration in serum are made mainly by pulmonologists and pediatricians, and occasionally by family physicians. In addition, some ␣ 1 AT-deficient patients are identified by protein electrophoresis. We measured the concentration of ␣ 1 AT antigen by immunonephelometry with a BN ProSpec Nephelometer calibrated with Certified Reference Material 470 (Dade Behring; CV, 1.6% at 0.9 g/L). Whenever we measured an ␣ 1 AT concentration below the lower limit of our reference interval (1.0 -3.5 g/L) during the last 5 years, we consulted with the requesting physician to determine whether further characterization of the finding by genotyping was indicated. This workup was approved by the hospital ethics committee. In addition, we genotyped 48 consecutive patients with ␣ 1 AT concentrations between 1.0 g/L and 1.5 g/L to confirm that we had missed no relevant disease-associated combinations of ␣ 1 AT alleles at the 1.0-g/L threshold.
␣ 1 AT GENOTYPING: DNA ISOLATION AND SEQUENCE ANALYSIS
After obtaining informed consent, we isolated the patient's DNA and amplified and sequenced relevant parts of the ␣ 1 AT gene (exons 2, 3, and 5) (see Table 1 for primer sequences). When requested, we also sequenced the ␣ 1 AT gene in family members of index patients who had been demonstrated to be homozygotes or compound heterozygotes for diseaseassociated alleles. We used the Puregene DNA isolation reagent set (Gentra Systems) according the manufacturer's instructions to prepare genomic DNA from EDTA-anticoagulated whole blood.
All amplification and sequencing primers were obtained from Applied Biosystems. PCR reaction mixtures contained 10 mmol/L Tris-HCl (pH 8.3), 50 mmol/L KCl, 1.5 mmol/L MgCl 2 , 0.2 mmol/L of each deoxynucleoside triphosphate, 0.3 mol/L of each primer, and 2.5 U of AmpliTaq Gold DNA Polymerase (Applied Biosystems). PCR products were sequenced with an ABI Prism 310 Genetic Analyzer (Applied Biosystems).
Results
With this workup, we identified 66 index patients (approximately 10% of the total number of requested ␣ 1 AT quantifications) who had an ␣ 1 AT concentration Յ1.0 g/L. Because the ␣ 1 AT gene is organized into 4 coding exons and 3 noncoding exons, as described above, and because the polymorphisms that affect ␣ 1 AT concentration and/or function are mainly located in coding exons 2, 3, and 5, we decided to sequence these exons first. We planned to sequence the rest of the gene in cases of discrepancies between the observed concentration and the genotype, but we observed no such discrepancies in our study population. Genotyping by direct sequencing revealed not only the frequently occurring S and Z alleles but also the M procida , M palermo , M 6passau , M wurzburg , and M heerlen alleles. We also discovered 2 previously undescribed null alleles (Tables 2 and 3 ), which we named Q0 soest and Q0 amersfoort , after the residences of the respective index patients. To confirm that we had missed no clinically relevant allele combinations in applying the 1.0-g/L threshold, we selected 48 individuals with ␣ 1 AT concentrations between 1.0 g/L and 1.5 g/L and sequenced ␣ 1 AT gene exons 2, 3, and 5. The results confirmed that we had missed no disease-associated allele combinations by placing the threshold at 1.0 g/L ( Table 2 ). The various alleles observed in this study and their respective effects on the concentration and/or function of the ␣ 1 AT protein concentration are listed in Table 3 (4-6, 11, 17-28 ) . Table 2 demonstrates that the wild-type MM genotype and the MS genotype (i.e., heterozygous for the S allele, which produces a minor ␣ 1 AT deficiency) rarely exhibit ␣ 1 AT concentrations Յ1.0 g/L (the lowest observed concentrations were 0.92 g/L and 0.86 g/L, respectively). This result is consistent with the fact that the MS genotype has not been associated with an increased risk for lung disease. The combination of the M allele with any deficient or null allele (Z, M procida , M palermo , M heerlen , and the newly identified Q0 soest and Q0 amersfoort alleles) produces mild to intermediate ␣ 1 AT concentrations in SZ compound heterozygotes are known to be insufficient to ensure lifetime protection of the lungs from proteolytic damage by elastase, especially in smokers (11 ) . Deficient ␣ 1 AT concentrations (Ͻ0.05 g/L-0.78 g/L) are observed in both ZZ homozygotes and compound heterozygotes for other deficient or null alleles (ZM heerlen , ZQ0 soest , and M heerlen Q0 amersfoort ).
The index patient for the Q0 soest allele was a 46-year-old man (JK) who had severe COPD and an ␣ 1 AT concentration of 0.22 g/L (Fig. 1A) . Sequencing revealed compound heterozygosity for the Z allele and this new null allele, Q0 soest . In this allele, the deletion of the A nucleotide in codon 102 (ACC 3 -CC) causes a 5Ј frameshift to produce a stop at codon 112 (Thr 102 3 stop 112 ). We suggest that premature termination in exon 2 produces an allele with no detectable mRNA production (21) (22) (23) . The Q0 soest allele is based on the M1 (Ala 213 ) founder allele. A risk inventory of the family of the index patient revealed that the partner of the index patient had the MM genotype and an ␣ 1 AT concentration of 1.4 g/L and that their 3 children had the MQ0 soest genotype with intermediately deficient ␣ 1 AT concentrations of 0.58 -0.76 g/L, as expected for carriers of a null allele. The mother of the index patient had the MZ genotype and an ␣ 1 AT concentration of 1.2 g/L, whereas the only sister of the index patient had the MM genotype and an ␣ 1 AT concentration of 1.5 g/L. These results suggest that the deceased father carried the MQ0 soest genotype. Coincidentally, a few months later we encountered a patient who had an ␣ 1 AT concentration of 0.73 g/L and also appeared to be heterozygous for the Q0 soest allele (MQ0 soest genotype). As far as we know, the 2 index patients are not related. The index patient for the Q0 amersfoort allele was a 47-year-old female patient (GH-B) who had an ␣ 1 AT concentration of 0.24 g/L and chronic pulmonary disease (Fig. 1B) . Sequencing revealed compound heterozygosity for the deficient M heerlen allele and the other new null allele, Q0 amersfoort . In this allele, a nonsense mutation creates a stop at codon 160, in the same codon as a mutation previously described for the Q0 granite falls allele (21 ) ( Table 3) . As with the Q0 granite falls allele, the Q0 amersfoort mutation produces a premature termination in exon 2, leading to an allele with no detectable mRNA production (21) (22) (23) . A risk inventory of the family of the index patient revealed that the partner of the index patient had the MM genotype (␣ 1 AT concentration, 1.4 g/L). Their 3 children carried the MM heerlen genotype, with ␣ 1 AT concentrations of 0.61-0.69 g/L. The mother of the index patient had the MQ0 amersfoort genotype and an ␣ 1 AT concentration of 0.65 g/L. Of the 2 sisters and 3 brothers of the index patient, 1 sibling had the MQ0 amersfoort genotype and an ␣ 1 AT concentration of 1.0 g/L. Coincidentally, a few months later we encountered an index patient who had an ␣ 1 AT concentration of Ͻ0.05 g/L and also appeared to be a compound heterozygote for the M heerlen Q0 amersfoort genotype. Again, the 2 index patients do not appear to be related.
Discussion
In many cases, COPD is caused by the combination of smoking and a genetic susceptibility (2 ) . Mutant genes, although rarely absolute predictors of the development of disease, generally predict a risk of disease that may be modified by environmental factors. When such environmental risk factors are known and minimized, the early identification of a genetic susceptibility may lead to substantial health benefits for the affected individual (30 ) . ␣ 1 AT deficiency is well known to reduce the protection of lung tissue from the activity of neutrophilic elastase, thereby leading to progressive destruction of lung tissue and finally to overt COPD Q0 amersfoort (Tyr 160 3stop) Nonsense mutation producing a stop at codon 160; occurs in the same codon as Q0 granite falls . Q0 granite falls is produced by deletion of C in the TAC codon, leading to a 5Ј frameshift and a resulting TAG stop codon, whereas Q0 amersfoort results from a transversion of the C for a G, leading to a TAG stop codon. As with Q0 granite falls , the mutation produces premature termination in exon 2 with no detectable mRNA ͓Nukiwa et al. (21 ) Risk inventory of the families of the index patient in which alleles Q0 soest (A) and Q0 amersfoort (B) were initially identified. ␣ 1 AT concentrations are indicated beneath the genotypes.
New Workup for ␣ 1 -Antitrypsin Deficiency (3, 5, 31, 32 ) . Besides smoking, the environmental risk factors for individuals with ␣ 1 AT deficiency include passive exposure to tobacco smoke, especially as a child, and exposure to mineral dust (33, 34 ) .
Clinically relevant ␣ 1 AT deficiency is often caused by homozygous inheritance of the ␣ 1 AT Z allele, but ␣ 1 AT deficiency can also be due to a combination of other deficient, dysfunctional, or null alleles at the ␣ 1 AT locus. For instance, ␣ 1 AT concentrations in SZ compound heterozygotes are thought to be insufficient to ensure lifetime protection of the lungs from proteolytic damage, especially in smokers (1, 4 ) . In addition, Dahl et al. (29 ) demonstrated that in the larger population even the MZ genotype (associated with intermediately deficient ␣ 1 AT concentrations) is associated with reduced pulmonary functions in individuals with clinically established COPD. Risk ratios for COPD range from 1.5-to 12-fold, depending on whether the deficient allele is present in heterozygous or homozygous allele combinations (29, 32 ) .
The ␣ 1 AT protein is a positive acute-phase responder, and we recommend that clinicians keep this fact in mind when setting a threshold for additional analyses to identify patients at risk. In our study, the highest concentration we observed in patients with disease-associated allele combinations was 0.78 g/L (observed in both a ZZ homozygote and an SM heerlen compound heterozygote). On the basis of the data in Table 2 , we suggest a threshold of 0.8 g/L (instead of the 1.0-g/L threshold in this study) for detecting all patients at risk, although additional analyses (either phenotyping or genotyping) are generally carried out whenever the ␣ 1 AT protein concentration is below the lower limit of the reference interval (4, 15, 16 ) .
In the present study, our sequence analysis of relevant parts of the ␣ 1 AT gene in patients with ␣ 1 AT concentrations below the lower limit of the reference interval (Յ1.0 g/L) revealed various deficient and null alleles at the ␣ 1 AT locus besides the frequently observed S and Z alleles. We identified 18 patients who were homozygotes or compound heterozygotes for alleles that produce a deficient ␣ 1 AT concentration. The frequencies of these deficient alleles among the 36 alleles of these 18 patients were as follows: Z, 61%; S, 17%; M heerlen , 11%; Q0 amersfoort , 6%; M wurzburg , 3%; and Q0 soest , 3%. The gold standard for the identification of ␣ 1 AT variants, according to the American Thoracic Society and the European Respiratory Society (15 ) , is the phenotyping of serum samples by IEF on thin-layer gels in a pH gradient (pH 4 -5). Phenotyping is technically challenging because of the complex microheterogeneity of the ␣ 1 AT protein, and severely deficient alleles and null alleles cannot be identified by this approach (16, 17 ) . In our study, up to 22% of the alleles that we found in disease-associated allele combinations (namely, M heerlen , Q0 amersfoort , M wurzburg , and Q0 soest alleles) would have been missed with IEFbased methods (16, 17 ) . In addition, many commercially available or laboratory-specific methods for ␣ 1 AT genotyping focus solely on the more prevalent S and Z alleles (16, 35 ) . These S/Z-genotyping assays require additional analysis (phenotyping or sequencing) when the patient with the observed genotype does not exhibit the expected serum ␣ 1 AT concentration. Such results prompt the question of what threshold to apply in such cases. Snyder et al. (16 ) suggest expected concentrations of Ͼ1.0 g/L for non-S/non-Z genotypes, Ͼ0.7 g/L for Z/non-S and S/non-Z genotypes, Ͻ1.0 g/L for the SS genotype, and Ͻ0.7 g/L for the ZZ genotype. The application of these thresholds to our group of 66 index patients would have required additional analysis for 20 (30%) of these patients. In addition, 2 of the patients (with the SM heerlen and SM wurzburg genotypes) would have been incorrectly typed as having the MS genotype. Of the 20 samples requiring additional analysis, 11 samples would have yielded interpretation problems with phenotyping because of the presence of severely deficient or null alleles, such as M heerlen , M wurzburg , Q0 soest , and/or Q0 amersfoort (17, 27, 28 ) . Given the availability of DNA-sequencing equipment in many hospitals, we therefore advocate direct sequencing of the relevant parts of the ␣ 1 AT gene for patients with suspected ␣ 1 AT deficiency. Direct DNA sequencing offers the advantage of clear-cut and efficient detection of any alteration in the wild-type sequence, including null alleles and the identification of previously unknown alleles. This approach not only leads to the unambiguous identification of combinations of alleles responsible for ␣ 1 AT deficiency in index patients but also offers the possibility of a risk inventory for their families. This capability is beneficial because recent studies have demonstrated that significant positive effects are associated with the early identification of ␣ 1 AT-deficient individuals (36 ) . Importantly, such effects would include an increased willingness to reduce exposure to environmental risk factors, such as cigarette smoking.
In conclusion, ␣ 1 AT deficiency is a common genetic disorder that predisposes an affected individual to COPD and/or liver disease. In many laboratories, a characterization of ␣ 1 AT deficiency implies the phenotyping of the protein by IEF and/or S/Z genotyping. Such an approach may lead to misdiagnosis because some alleles (e.g., null alleles) will be missed. We advocate a workup that includes genotyping by direct sequencing of the coding regions of the ␣ 1 AT gene for patients who have ␣ 1 AT concentrations Յ1.0 g/L. Application of this approach means that no relevant disease-associated allele combinations will be missed. Finally, with this approach we have identified 2 previ-ously unidentified null alleles, Q0 soest and Q0 amersfoort , that produce ␣ 1 AT deficiency.
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